Marathon Pharmaceuticals LLC, of Northbrook, Ill., said that it is expanding patient access to deflazacort, its investigational medicine for Duchenne muscular dystrophy (DMD) by making it available to qualified patients, at no cost, through a growing network of medical research centers across the country.